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Abstract 
Since their inception in pharmaceutical applications, physiologically-based kinetic (PBK) models are 
increasingly being used across a range of sectors, such as safety assessment of cosmetics, food 
additives, consumer goods, pesticides and other chemicals. Such models can be used to construct 
organ-level concentration-time profiles of xenobiotics. These models are essential in determining the 
overall internal exposure to a chemical and hence its ability to elicit a biological response. There are a 
multitude of in silico resources available to assist in the construction and evaluation of PBK models. 
An overview of these resources is presented herein, encompassing all attributes required for PBK 
modelling. These include predictive tools and databases for physico-chemical properties and 
absorption, distribution, metabolism and elimination (ADME) related properties. Data sources for 
existing PBK models, bespoke PBK software and generic software that can assist in model 
development are also identified. On-going efforts to harmonise approaches to PBK model 
construction, evaluation and reporting that would help increase the uptake and acceptance of these 
models are also discussed. 
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1. Introduction 
The science of physiologically-based kinetic (PBK) modelling has been evolving in recent years, 
contemporaneously with developments in computational approaches across multiple sectors. Whilst, 
historically, data for models were obtained via time and resource intensive animal experimentation, 
there is now an array of in silico resources that can assist with the parameterisation, computational 
implementation and evaluation of these models. The role of internal exposure, in particular organ-
level concentration-time profiles of xenobiotics, in determining true potential to elicit a biological 
response, is now recognised across multiple disciplines from drug development to chemical safety 
assessment of cosmetics, food additives, consumer goods, pesticides and other chemicals to which 
humans (and animals) are daily exposed. A recent report by Paini et al., 2017 [1] demonstrated the 
distinct upward trajectory in the use of PBK models over the last 30 years with respondents to a survey 
indicating a significant number of models being applied in chemical safety assessment. Other uses 
included experimental design, drug design, ecological health risk assessment, veterinary health, 
informing pharmaceutical dose selection for specific populations, clinical trial design and drug 
labelling. PBK models are being increasingly used to extrapolate from in vitro experimental data to in 
vivo scenarios (in vitro to in vivo extrapolation; IVIVE) in response to the ethical, societal and 
economical drivers to move away from in vivo animal experiments and towards new approach / next 
generation methodologies  (NAM / NGM) [2], [3], [4]. Rowland et al., 2015 [5] discussed the increased 
number of submissions, containing PBK models, to regulatory agencies concerned with clinical drug 
development. Meetings organised by the US Food and Drug Administration (FDA; [6]) and the UK 
Medicines and Healthcare Products Regulatory (MHRA), in collaboration with the Association of British 
Pharmaceutical Industry (ABPI; [7]) centred on developing best practice in building and reporting PBK 
models and enhancing common understanding between regulators, academia and industry 
encouraging further use of PBK modelling. Recent US FDA guidance proposes appropriate format and 
content for submissions of physiologically based pharmacokinetic (PBPK) analyses for new drug / 
biologic license applications. Relevant publications were highlighted concerning key topics such as 
study design, specific populations (paediatrics, pregnancy, disease states) and potential drug-drug 
interactions [8]. 
Clearly, the use of PBK models across a range of disciplines is rapidly expanding. Laroche et al., 2018 
[9] summarise recent developments and needs across multiple sectors i.e. pharmaceuticals, vaccines, 
cosmetics, fragrances, chemical, agrochemical and food industries. The aim of this paper is to present 
an overview of the in silico resources available to assist in PBK model construction and evaluation, that 
is relevant across the boundaries of the different sectors. It is recognised that such an overview can 
never be truly complete as continual developments inevitably lead to changes in availability and 
capabilities of the software and databases recorded. However, at the time of writing, the information 
provided is as comprehensive as reasonably practicable and provides a “one stop shop” to signpost 
the various resources available. It is intended that this will not only provide a useful starting point for 
those relatively new to the field but also may identify additional, unexploited resources for 
experienced modellers. 
2. Applications of PBK models 
The foundations for PBK modelling were laid with the introduction of physiologically-based 
pharmacokinetic (PBPK) modelling which was used to describe the time course of pharmaceuticals 
within different organs or tissues of the body [10], [11]. This tool has also been applied to evaluate 
the health risks posed by environmental chemicals –  referred to as physiologically-based toxicokinetic 
modelling (PBTK) defined by the World Health Organization as “a model that estimates the dose to 
target tissue by taking into account the rate of absorption into the body, distribution and storage in 
tissues, metabolism and excretion on the basis of interplay among critical physiological, 
physicochemical and biochemical determinants‟ (WHO, 2010,[12]). Being adaptable to individual 
physiology, these models enable internal exposure, hence potential therapeutic and adverse effects, 
to be predicted more accurately than models relying on external dose alone. For example, models can 
be parameterised for altered kidney or liver function as may be expressed by elderly or neonatal 
populations or pregnant women. The models can be extrapolated to take into account the effects that 
age, disease state or genetic variation may have on concentration-time profiles. Clinically, this enables 
appropriate dose adjustments to be more reliably predicted, optimising therapy for sensitive 
individuals, hence their increasing application in this area. Previously, in drug development many PBK 
models have focused on key organs having a significant effect on ADME properties of drugs, however, 
more recent applications specifically consider organs associated with toxicity and side effects in terms 
of safety assessment. For example, Pilari et al., 2017 [13] include organs of the reproductive and 
endocrine systems (testes and thyroid) in an extended PBK model more relevant to toxicity prediction. 
PBK models can also be applied to address issues of drug-drug (or drug-food; drug herbal product) 
interactions, where the presence of one drug (component of food or herb) may inhibit or induce 
metabolising enzymes or compete for transporters used by a co-administered compound. This can 
lead to a significant increase or decrease of circulating drug levels causing loss of therapeutic effect or 
induction of side effects. The application of such models also goes beyond predicting effects of 
pharmaceutical agents, similar considerations are important where excipients have been shown to 
exert undesirable biological effects. Valeur et al., 2018 [14] stipulate that increased knowledge is 
required in terms of understanding the effects of excipients present in drug formulations, particularly 
with respect to potential toxicity in neonates who may, for example, show differences in metabolic 
capacity. PBK models, specifically adapted to the physiology of neonates, may provide important 
information to optimise treatment for these patients. PBK models are playing a pivotal role in several 
ongoing European Horizon 2020 projects that are exploiting the full potential of in-silico medical 
research to generate virtual patient/population libraries as well as data integration and data-driven 
in-silico models for enabling personalised medicine within a harmonised framework. 
In addition to drugs, PBK models have been also been applied to the safety assessment of food, 
cosmetics and environmental chemicals. In the food industry, PBK models have been applied to 
assessing the health risks from exposure to pesticides, contaminants and food contact materials. The 
models enable multiple exposure scenarios, interspecies differences and intraspecies variation to be 
accounted for when predicting internal exposures. The scientific report of the European Food Safety 
Authority (EFSA) (2014) reviews many of these applications of PBK modelling in the food safety sector. 
For cosmetics and personal care products, the Notes of Guidance from the Scientific Committee on 
Consumer Safety (SCCS) (2016) explicitly recognise contributions from PBK models in safety 
assessment. Recently published Opinions of the SCCS (for example opinion on phenoxyethanol 
SCCS/1575/16) have incorporated data from PBK studies. Tan et al., 2018 [15] review the use of PBPK 
modelling in terms of public health decision making concerning environmental chemicals. Their report 
found that from 1977 – 2016, 65% of published models (identified using the PubMed database) related 
to environmental chemicals, and 31% related to drugs. While the potential of PBPK modelling has 
been recognised, barriers to uptake by public health agencies persist particularly because of a lack of 
expertise in the area - there is a limited number of people with sufficient expertise to build, evaluate 
and review models. These problems are exacerbated by a lack of consistency in the format of 
submissions. Additional issues identified in the report were problems of transferring models between 
platforms and lack of confidence in extrapolation. Several of these issues, and potential solutions, are 
discussed below. The application of PBK models to nanoparticles is another area of increasing interest. 
In 2010 Li et al discussed the factors to be considered when applying the models to nanoparticles, 
such as differences in metabolism, distribution and accumulation in the lymphatic system which can 
differ between nanoparticles and small molecules [16]. More recently Yuan et al reviewed the 
disposition properties of nanoparticles and how PBK models could take account of the unique 
characteristics of these particles [17]. A comprehensive review of PBK models for nanoparticles, and 
their acceptability for regulatory purposes was also recently published by Lamon et al [18]. The 
authors identified similar issues to those discussed by Tan et al [15] in relation to the problems that 
hindered regulatory acceptance: complexity of models; transferability across platforms and; lack of 
confidence in models where tissue/plasma concentration data are lacking [18]. In regulatory 
toxicology, there is an ethical and economical desire to move away from animal experiments to 
alternative methods, such as in vitro testing. PBK modelling has an important role to play in 
extrapolating in vitro concentration-effect information to in vivo human dose-response relationships 
(IVIVE). This enables points of departure to be identified from in vitro studies for risk assessment 
purposes. Punt et al., 2011 [19] describe the successful application of this approach in terms of 
promoting alternatives to animals in risk assessment. Whilst the above demonstrates great variety in 
the types of chemicals investigated using PBK modelling, the model structures themselves are 
independent of the nature of the chemical. 
3. Input parameters required for PBK model building 
Figure 1 shows a characteristic representation of a PBK model structure in the centre of the image. 
Inputs typically required for modelling are shown on the right, and an example model output is shown 
on the left (the concentration-time curve for a specific chemical in a tissue or organ of interest). Within 
each compartment it is possible to incorporate more detailed model structures, for example the 
gastro-intestinal (GI) tract may be subdivided into individual compartments – stomach, duodenum, 
jejunum, ileum, caecum and colon with dissolved and undissolved chemical being considered 
separately. The predictive performance of a model can be evaluated by comparing experimentally-
derived data (where available) with model-derived values.  
[FIGURE 1 – HERE] 
Development of PBK models requires both chemical specific parameters (e.g. metabolic rates, plasma 
protein binding fraction, dermal absorption rate) and chemical independent system information -   
physiological and anatomical values (e.g. blood flows and tissue volumes). Chemical specific factors 
may be derived from experimental measurements or predicted using an ever-increasing array of 
software available to predict these factors. Key properties relate to the ability to partition across 
biological membranes, hence the logarithm of the octanol: water partition coefficient (log P), aqueous 
water solubility and pKa (relating to potential for ionisation – in general unionised molecules cross 
biological membranes more readily) are commonly used to estimate those factors needed for a PBK 
model. In addition there are a multitude of in silico models that predict the absorption, distribution, 
metabolism and elimination (ADME) of chemicals. These include models for absorption through the 
gastro-intestinal tract (or surrogates thereof, such as PAMPA or CaCo-2 membranes), partitioning 
across the blood brain barrier, permeation through skin, plasma protein binding and extent of 
distribution throughout the body (volume of distribution). A limited number of models also exist for 
more specific ADME properties, such as partitioning into milk or blood: testes concentration ratio. 
Patel et al., 2018 [20] have collated and reviewed over 80 of these ADME related models. One of the 
more difficult properties to predict using in silico methods is clearance; accurate estimation of 
clearance is essential as this determines the overall residence of a chemical in the body. For this 
reason, in vitro estimation of hepatic clearance is still the predominant method used to obtain such 
information using liver slices, or (sub) cellular fractions, however, total clearance (i.e. clearance by all 
routes including metabolism, biliary, renal clearance etc.) influences overall internal exposure. 
Similarly, although there are datasets for thousands of chemicals for which plasma protein binding 
has been measured and many in silico models derived from these data, measurement of plasma 
protein binding for new chemicals of interest is often undertaken as this parameter can have a 
significant effect on PBK model predictions. In vitro measurements, using human derived tissue, are 
clearly important sources of information for PBK model development, however, as the focus of this 
review is on in silico methods, information will be restricted to data sources for in vitro information 
rather than experimental details. 
Multiple data sources are available providing system information i.e. the physiological and anatomical 
reference values on which PBK models are predicated. These include data for multiple species, life 
stages - from gestational development to the elderly, and disease-related adaptations to standard 
values. Much of this data has been empirically derived and collated over decades. In the next section 
each of the various types of input parameter for PBK models are considered individually and in silico 
resources for obtaining this information are identified. Whilst individual sources for the information 
are given, it is recognised that much of the collated information has been brought together in bespoke 
PBK modelling software that can provide, both key information for components of a model and an 
overall modelling platform; these are also identified below. 
4. In silico resources available to assist in PBK model construction and evaluation 
The following section illustrates the range of information, relevant to PBK model construction and 
evaluation, that is available from a wide variety of sources. These resources have been collated into 
eight tables, each relating to different components of PBK modelling or ancillary information. The 
contents of the tables are briefly summarised here; details on the availability and capabilities of the 
software, models and datasets are provided in tables 1-8. The resources have been collated here for 
information only. The authors have not evaluated each of these resources; their inclusion should not 
be considered an endorsement. 
4.1 Resources for external exposure 
Although not strictly associated with development of PBK models, Table 1 includes information on 
models for external exposure, as without an estimation of the amount to which the body is exposed 
externally there can be no estimation of internal exposure from a reliable PBK model. For drugs the 
precise amount and route of exposure are known making this a relatively simple “exposure” scenario. 
Dosing information for clinical applications across age groups can be obtained from resources such as 
Medicines Complete (refer to Table 1). For chemicals that humans (and animals) are exposed to via 
food, use of personal care or household cleaning products, or from the environment, the extent of 
exposure is more difficult to estimate. However, tools are available to provide estimates for these 
different scenarios. For example: EFSA provides estimates for dietary exposure; SCCS provides typical 
product usage for personal care products; the European Centre for Ecotoxicology and Ecotoxicity 
(ECETOC), the United States Environmental Protection Agency (US EPA) and the Dutch National 
Institute for Public Health and the Environment (RIVM), amongst others, provide models for predicting 
worker or consumer exposure to household products and environmental pollutants. A summary of 
these external exposure models is provided in Table 1. 
4.2 Resources for obtaining physico-chemical properties 
Knowledge of physico-chemical properties is important not only in terms of PBK modelling, for 
predicting uptake and distribution within the body (as indicated above), but also forms part of the 
fundamental characterisation data for chemicals. As such, there is a large number of databases 
reporting experimental values as well as predictive software both freely available and commercial 
from which to obtain these properties. Resources such as Chemspider (from the Royal Society of 
Chemistry), ACD / Percepta (from ACD laboratories) and EPISUITE (from the US EPA) provide estimates 
and/or measured values for log P, water solubility, vapour pressure, pKa etc.  A number of these 
resources are indicated in Table 2. Several of these resources are also capable of predicting ADME-
related properties, for example ADMET Predictor from Simulations Plus predicts log P, log D, solubility 
in intestinal fluid as well as permeability across skin, blood-brain barrier, interactions with proteins, 
transporters and other properties.  
4.3 Resources for obtaining ADME-related information 
Table 3 provides a compilation of predictive software, datasets and models for more than 50 ADME 
related endpoints. The amount of data and number of models available is highly variable depending 
on the endpoint in question. Thousands of measured values are available for plasma protein binding 
data along with many predictive models, similarly there are many data and models for intestinal 
absorption, blood brain barrier partitioning, skin permeation, p-glycoprotein and transporter binding. 
Whilst there are many data for renal, hepatic and total clearance, there are fewer, accurate models 
for these endpoints, reflecting the difficulty of developing in silico models for such endpoints. This was 
highlighted in the report of Paini et al., 2019 [21] who identified hepatic clearance as a key input 
parameter for PBK models that was better derived from in vitro studies where possible. For highly 
specific information, for example tissue concentration-time profiles (that may be used to evaluate PBK 
model outputs), very few data are available. The on-line chemical modelling environment (oCHEM) 
provides some such data but provides much more extensive datasets for more standard endpoints 
such as inhibition of cytochrome P450 enzymes, CACO-2 permeability or fraction unbound (fraction 
unbound is of importance as it influences the extent to which a chemical distributed within the body). 
The paper of Przybylak et al., 2018 [22]  is useful in this regard as it identifies over 140 ADME related 
datasets that can be used for development of new models; these models can be used to predict 
parameters for chemicals where experimental data are lacking. 31 of the datasets were considered as 
“benchmark” datasets, particularly suitable for modelling purposes (these were converted to Excel 
format and are available as supplementary information within the paper). Given the increasing focus 
on ADME properties in determining true potential to elicit a biological response, it is not surprising 
that the amount of software and data compilations in this area is expanding rapidly. Data are now 
available for multiple species and multiple ADME/PK endpoints ranging from computational ligand-
protein interaction studies to clinical observations as illustrated by the diversity of resources in Table 
3.  
4.4 Resources for physiological and anatomical reference values 
Whilst the focus of tables 2 and 3 is on the chemical-specific input parameters, Table 4 provides 
resources for the chemical independent physiological and anatomical reference values that are also 
required for PBK modelling. Resources, such as Brown et al., 1997 [23] and the Interspecies Database 
(from RIVM and the Dutch ministry of Health Welfare and Sports) 
(https://www.interspeciesinfo.com/) provide parameter values for organs (weights, volumes, 
composition, percentage of cardiac output, local blood flow etc.) for multiple species. The 
International Commission on Radiological Protection (ICRPP) provides age and gender-related values 
for humans and are commonly used for fundamental input values – other similar resources are also 
given in Table 4. Increasingly PBK frameworks for specific organ structures are being developed and 
published, as well as being incorporated into PBK modelling software (such as SimCYP from Certara). 
Examples of these include: the models of Abduljali et al., 2018; 2012 [24], [25], [26] providing 
parameters for different stages of pregnancy and foetal development; the blood brain barrier/ brain 
compartment penetration models of Ball et al., 2013 [27], Gaohua et al., 2016 [28] and Zakaria et al., 
2018 [29], the models for lung from Goahua et al., 2015 [30] and the testes and thyroid models from 
Pilari et al., 2017 [31]. Obviously, a major source of PBK modelling parameters are previously published 
PBK models, these models may serve as a template for deriving models for similar chemicals. In 2016, 
Lu et al., [32] published a Knowledgebase summarising 307 published PBK models along with a study 
demonstrating how information from these could be used to develop PBK models for other similar 
chemicals. Concepts relating to similarity and selection of chemicals, for which PBK models are 
available that can be used as templates for other chemicals, are discussed further below. 
4.5 Physiologically-Based Kinetic modelling software 
The number of bespoke PBK modelling packages available has been gradually increasing with freely 
available applications now making the area more accessible to a larger number of researchers; some 
of these are indicated in Table 5. The Simcyp Simulator software from Certara 
(https://www.certara.com/), in particular, is widely used by industry. The software incorporates a 
number of databases (physiological and anatomical data, genetic and epidemiological information) 
and model structures (e.g. those identified in Table 4) to enable organ-level predictions of 
concentration-time curves for specific human subpopulations, as well as modules for rats, dogs and 
knock-out mice. Cloe from Cyprotex (now part of Evotec AG) is another example of a complete PBK 
modelling package enabling organ concentration-time curves to be generated for humans, rats and 
mice. Freely available software includes: PK-Sim and MoBi (Bayer) – a PBK modelling tool with 
integrated databases for different species and capable of multiscale modelling; MEGen (Health and 
Safety Laboratory, UK) – a method to rapidly generate PBK model code; and more recently PLETHEM 
(Scitovation) which incorporates an 11 compartment PBK model and an IVIVE model relating in vitro 
points of departure to equivalent in vivo values. 
4.6 Software to assist development of pharmacokinetic/pharmacodynamic models 
Aside from the bespoke PBK modelling software indicated above, there are numerous applications 
that can assist in developing PBK or pharmacokinetic/pharmacodynamic (PK/PD) models. The website 
for Pharmacokinetic and Pharmacodynamic Resources (http://www.pharmpk.com/soft.html) lists 
over 100 such applications and the reader is referred to that resource for a more up-to-date and 
comprehensive listing. Examples of this type of application include routines for PK/PD simulations, 
analysis tools, non-linear mixed effect modelling and simulation software. PopGen from Bayer enables 
virtual populations to be considered and ChemPK from Cyprotex can predict PK data including 
clearance, maximum concentration in tissue (Cmax), time to reach the maximum concentration (Tmax,) 
and the area under the concentration-time curve (AUC) from oral and intravenous dosing. The RVis 
platform is currently under development at the Health and Safety Laboratory, UK, this can load, run 
and visualise outputs from models, with applications in IVIVE and sensitivity analysis, enabling the 
evaluation of PBK model structure and performance (Paini et al., 2017,[1]). These software and other 
examples are summarised in Table 6. 
4.7 Generic mathematical and computational software that can be applied to issues in PBK modelling 
Of the numerous research fields that exist at the interface of chemistry and biology, PBK modelling is 
more amenable than most to solutions from mathematical and computational sciences. Many of the 
issues relating to behaviour of chemicals within compartments, linked by vessels and showing 
definable increases and decreases over time - in part dependent on volumes and flow properties - are 
in many ways akin to engineering scenarios. Consequently, in terms of computational solutions there 
are many examples of software or simplistic programmes that can assist in coding and solving for 
differential equations in PBK models, although originally developed for other purposes. Berkley 
Madonna is one example of a platform commonly used for PBK modelling, it is in essence a differential 
equation solver that can also be used for other dynamical modelling problems. Other examples of 
mathematical modelling software that can assist in PBK modelling are GNU MCSIM, SigmaPlot, 
applications within Rstudio and Matlab (within which the SimBiology toolbox possesses customisable 
PK models and the ability to perform simulations for individuals or populations). Sensitivity analysis, 
important for determining the significance of individual model parameters, can be performed by PBK 
and PK/PD modelling-specific software (Tables 5 and 6) as well as more generic mathematically-based 
software. Examples of more generic resources that can be applied to issues in PBK modelling are given 
in Table 7.  
4.8 Software to identify structurally similar chemicals 
As discussed above, identifying a chemical, for which a PBK model has already been published (source 
chemical(s)) can provide key information for developing or evaluating a PBK model for a similar 
chemical of interest for which no model is available (target chemical). The concept of reading across 
information from source chemical(s) to a target chemical is well-established within regulatory 
toxicology. A great deal of guidance is available on how to select similar chemicals and report a read-
across prediction (Read Across Assessment Framework, ECHA (2015); [33]). This concept is now being 
increasingly applied to PBK model development. The key to the process is selecting the most 
appropriate source chemicals from which to read-across information and fully justifying the selection. 
One difficulty is that no chemical can be absolutely similar to another, they can only be similar in terms 
of given properties. In Table 8, several computational methods to identify structurally similar 
chemicals are given. However, the choice of similarity metrics used can have a significant effect on 
which chemicals are identified as most similar. In terms of selection based purely on structural 
similarity, a consensus from several similarity metrics may be more appropriate. Recent publications 
have addressed this issue specifically in terms of selecting source chemicals to develop or evaluate 
PBK models for target chemicals. Ellison, 2018 [34] selected source chemicals using structural 
properties (functional group, scaffold, metabolism, physico-chemical properties and chemical 
fingerprints) and functional similarity (i.e. in the same classes according to the Biopharmaceutics 
Disposition Classification System and Extended Clearance Classification System; the same likelihood 
of being a p-glycoprotein substrate; and similar volumes of distribution, bioavailability and systemic 
clearance). The results showed that the approach could be used to successfully predict the 
pharmacokinetic profile of target chemicals using appropriately selected source chemicals. Lester et 
al., 2018 [35] further explored the concepts of selecting source chemicals, emphasising the need to 
incorporate expert judgement as part of the process. The authors devised “rating rules” for selecting 
chemicals where expert judgement was included in a structured, less subjective approach. Table 8 
includes examples of similarity approaches applied to the issue of PBK modelling including those of Lu 
et al., 2016 [32], Lester et al., 2018 [35] and Ellison, 2018 [34]. This issue of identifying “similar” 
chemicals is currently an area of intense research in many sectors both within European projects (e.g. 
the Innovative Medicines Initiative eTRANSAFE project (http://etransafe.eu/) for translational safety 
assessment of medicines) and at the global level through projects being developed via the 
Organisation for Economic Cooperation and Development (OECD). Hence, more guidance on selecting 
similar chemicals, and justifying the selection, is anticipated. 
[TABLES 1-8 HERE] 
 
5. Conclusions and outlook 
A multitude of in silico resources have been presented herein to assist researchers in the development 
and evaluation of PBK models. This should provide a useful starting point to those new to the area as 
well as signposting additional resources to more experienced researchers who may not be aware of 
developments in all of these resources. Bessems et al., 2015 [36] stipulated the need for 
“comprehensive 'one-stop' web-based kinetic modelling portals”, ideally incorporating or linking to 
freely available kinetic modelling tools and databases, to facilitate kinetic modelling. This collation of 
resources serves as a single resource identifying tools and databases to assist in PBK model 
construction and evaluation. 
Whilst many resources are available it is clear that there are several gaps not only in the underlying 
knowledge but also in the way in which the information is organised and stored. In terms of chemical-
specific input parameters, large datasets of measured values and reasonable quality predictive models 
are available for certain endpoints. Some literature models may be reproduced readily and a range of 
software are available; predictions will be more reliable forforchemicals falling within the applicability 
domain of the model; predictions for chemicals outside of the applicability domain will have greater 
uncertainty. For other endpoints, notably renal and hepatic clearance, there are far fewer reliable in 
silico models and this, therefore, should be a focus for continuing modelling efforts, notwithstanding 
the improvements in in vitro techniques in this area. More experimental data are needed to develop 
these models, particularly differential enzyme and transporter expression / activity both across 
different tissues within a given animal and across different species. Scaling anatomical properties 
(such as organ weights) works reasonably well across species, however, other factors scale less well. 
For example scaling the number of hepatocytes from in vitro systems to that in an adult liver is possible 
but does not correspond to an accurate scaling of intrinsic clearance in vitro to human data [5]. Where 
improvements can be made on any aspect of the input parameters for PBK models, this leads to 
greater accuracy and reduced uncertainty of the model.  
An important aspect to consider in developing and evaluating PBK models is the shift away from 
animal data to next generation physiologically-based kinetic (NG-PBK) models where data from in vitro 
and/or in silico studies replace in vivo data. Whilst there is some reluctance, particularly amongst 
regulatory organisations to accept such models in safety assessment, there are a number of ongoing 
activities to support this shift. More training and guidance, along with increased communication 
between the model developers and regulators have been proposed to increase acceptance of PBK 
models without animal data [21]. Whether or not a PBK model is considered acceptable depends on 
the intended purpose of the model; for example regulatory acceptance for safety assessment has 
more stringent criteria than models for in-house prioritisation. In accordance with Occam’s Razor, the 
simplest model capable of describing chemical behaviour, with sufficient accuracy for the problem in 
question, should be employed. 
Software developments, particularly the expansion of bespoke PBK modelling platforms available will 
be of great benefit to the area, particularly where freely available platforms increase accessibility for 
researchers. Community development of individual modules / subroutines that can be brought 
together in larger workflows or programming applications has shown to be a successful model for 
collaborative effort in both the R and KNIME environments. This is also a promising approach for 
continuing development of PBK models, where cross-sector collaboration between food, cosmetic, 
chemical and pharmaceutical industries can be used to resolve common problems.  
Using data from source chemicals to make predictions for target chemicals is widely used for other 
applications (for example toxicity prediction in regulatory toxicology) and recent developments have 
demonstrated the utility of this approach for PBK modelling. Already, very useful methods to find 
similar chemicals have been published in the literature (such as Ellison 2018 [34]) and as more 
knowledge and tools become available to ascertain which chemicals are similar, this will advance this 
approach further. This highlights one outstanding issue that is, being able to rapidly identify chemicals 
for which PBK models have already been developed. The Knowledgebase developed by Lu et al., 2016 
[32] is an excellent example of how existing models could be curated and made readily available for 
other researchers. Systematic reviews are now an established method to find, organise and extract 
information from literature studies. Data retrieved and search criteria being recorded in such a way 
as to enable subsequent researchers to readily update information in future. Ongoing systematic 
review of available PBK models is highly recommended to ensure maximum use can be made of 
published models. To this end a single repository for storing key information on published PBK models, 
would be highly beneficial, such a repository would benefit from consistency in the reporting of 
models. Following from an international workshop in this area, Loizou et al., 2008 [37] discussed the 
importance of developing good modelling practice (GMP) for PBPK modelling to assist model sharing, 
evaluation and consistency of application. Seven elements were proposed for a summary report with 
more detail being made available to specialists as necessary. The recommendations were for: an 
introduction including problem formulation/model applicability; a description of the model; metabolic 
information; relationship to mode of action; prediction of distribution accounting for human 
variability; an overview of uncertainty and sensitivity analysis; source of further information. More 
recently, the US Food and Drug Administration Center for Drug Evaluation and Research (FDA CDER) 
[38] has published guidance for industry on the format and content for reporting results from PBPK 
analysis to the FDA. This sets out clear recommendations for what to include in each of six sections of 
the report. Briefly, reports should include: a succinct overview of the model; a summary of the drug’s 
physico-chemical PK and PD properties; sufficient methodological information to allow model 
reproduction and evaluation (with appropriate workflows / decision trees); all system-specific and 
drug specific parameters, their source, assumptions and uncertainties (as tables); a description of the 
simulation conditions; software name, version and parameterisation; model verification and 
application details; key conclusions; cross-referencing to other relevant reports and supplementary 
documentation as necessary. If consistent model reporting were more widely taken up by the 
modelling community this would again provide long term benefits to the field.  
The BioModels database [39], provided by the European Molecular Biology Laboratory – European 
Bioinformatics Institute EMBL-EBI; https://www.ebi.ac.uk/biomodels-main/) provides a repository of 
computational models of biological processes. Models are manually curated from the literature and 
made publicly available; if the model is reproducible it is listed as a curated model, if not then it is 
listed as a non-curated model. At time of writing very few PBK models are reported in this system, 
however, expansion of this resource could potentially make a useful repository for PBK models for 
other users to exploit. PBK-related software, such as GNU-MCSim and PK-Sim / MoBI are compatible 
with Systems Biology Markup Language (SBML; http://sbml.org/) which provides a machine-readable 
interchange format for computer models of biological processes. This enables key components of 
models to be shared in different software environments without the need to rewrite the models, so 
making them more accessible to other users, increasing model longevity and adaptability. 
Capacity building in PBK model development and understanding amongst researchers from diverse 
fields has also been recognised as a clear need for future development. Jones and Rowland-Yeo (2013) 
[40] provide an excellent tutorial to explain the concepts of PBPK – components, parameters and 
applications in early stage and clinical drug development for those who are new to the area. More 
training material would help to move PBK model development from a niche to a more mainstream 
field of research, increasing the number of people able to review, interpret and use the models to 
make more accurate predictions of biological activity across life-stages, subpopulations and species. 
These developments give rise to boundless opportunities to apply PBK modelling to resolve many of 
the questions in in vitro to in vivo extrapolation, ecotoxicology (particularly bioaccumulation across 
species), veterinary science and human health.  
Disclaimer: The U.S. Environmental Protection Agency has provided administrative review and has 
approved this paper for publication.  The views expressed in this paper are those of the authors and 
do not necessarily reflect the views of the U.S. Environmental Protection Agency. 
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 Table 1. Resources to predict external exposure  
Resource Available from Brief summary of capability 
Computational 
Toxicology DashboardF 
https://comptox.epa.gov/d
ashboard    [41] 
Provided by United States Environment Protection Agency (USEPA); the dashboard hosts a repository of 
data for 762,000 chemicals and includes links to exposure prediction and monitoring data 
ConsExpo WebF https://www.rivm.nl/en/co
nsexpo 
Mathematical model to assess exposure to chemicals from everyday consumer products (e.g. household 
cleaning products and personal care products (provided by the National Institute for Public Health and 
the Environment, Netherlands); considers inhalational, oral and dermal exposure 
EC SCCS Notes of 
GuidanceF 
http://ec.europa.eu/health
/scientific_committees/con
sumer_safety/docs/sccs_o
_190.pdf   [42] 
European Commission Scientific Committee on Consumer Safety (EC SCCS) Notes of Guidance 9th 
revision: tables for exposure area, frequency of application, typical product usage etc. for personal care 
products 
ECETOC TRAF http://www.ecetoc.org/too
ls/targeted-risk-
assessment-tra/ 
Targeted Risk Assessment (TRA) tool provided by the European Centre for Ecotoxicology and Toxicology 
of Chemicals (ECETOC); calculates risk of exposure from chemicals to workers, consumers and the 
environment 
EPA ExpoBoxF https://www.epa.gov/expo
box 
This toolbox is a compilation of exposure assessment tools linking to guidance documents, databases, 
models etc. It is organised into six areas: approaches, media, routes, tiers and types, lifestages and 
populations and chemical classes 
EPA ExpoCastF https://www.epa.gov/che
mical-research/rapid-
chemical-exposure-and-
dose-research 
High Throughput exposure estimation for chemicals (complimentary to the EPA ToxCast program) for 
both environmental and consumer product exposure 
FAIM / FEIM EFSAF https://www.efsa.europa.e
u/en/applications/foodingr
edients/tools 
Food Additives / Enzyme Intake models (FAIM / FEIM) from the European Food Safety Authority (EFSA); 
estimates chronic dietary exposure to food additives / enzymes for different populations (based on 
collected food consumption data for different countries) 
 Medicines CompleteC https://about.medicinesco
mplete.com/  
Dosing information for different uses and age groups 
MerlinExpoF https://merlin-expo.eu/ Modelling Exposure to chemicals for Risk assessment: a comprehensive Library of multimedia and PBPK 
models for integration, prediction, uncertainty and sensitivity analysis; library of models to assess human 
and environmental exposure 
SHEDS (Stochastic 
Human Exposure and 
Dose Simulation 
(SHEDS)F 
https://www.epa.gov/che
mical-research/stochastic-
human-exposure-and-
dose-simulation-sheds-
estimate-human-exposure 
Probabilistic models to estimate total exposure of populations over time via inhalational, dermal, dietary 
and non-dietary routes. 
StoffenmanagerF 
(substance manager) 
https://stoffenmanager.nl/ Web-based quantitative exposure modelling tool for both respiratory and dermal exposure. 
FFreely available; CCommercial 
Additional sources of information: 
 The report of the World Health Organisation (International programme on chemical safety, Environmental Health Criteria 242, Dermal Exposure, 2014, 
ISBN 978 92 4 157242 2) includes a review of several models for estimating (dermal) exposure including DREAM, DERM, Calendex, EASE, MEASE, 
ECETOC TRA, RISKOF DERM, BEAT, ConsExpo, SprayExpo, SHEDS-R etc. 
 
 
 
  
 Table 2. Resources for obtaining or predicting physico-chemical properties  
Resource Available from Properties / Information  Additional Information 
ACD /PerceptaC  
(ACD Labs) 
https://www.acdlabs
.com/products/perce
pta/ 
Log P; log D; pKa; Abraham 
solvation parameters (relating 
to hydrogen bonding ability, 
polarizability, volume and 
partitioning)P 
Platform comprising modules for prediction of physico-chemical properties, ADME 
and toxicity 
ADME SARfari 
(EMBL-EBI)F 
https://www.ebi.ac.
uk/chembl/admesarf
ari/        [43] 
Log P; log D (reports values 
from ACD); PSA; M,P   
The European Bioinformatics Institute – part of the European Molecular Biology 
Laboratory provides a comprehensive range of molecular data resources for a range 
of research purposes 
ADMETlabF http://admet.scbdd.
com/calcpre/index/  
[44] 
Log P; log D; log S Application developed by the Computational Biology and Drug Design Group, Central 
South University, China 
ADMET PredictorC 
(SimulationsPlus) 
https://www.simulat
ions-
plus.com/software/a
dmetpredictor/ 
Log P; log D; pKa; diffusion 
coefficient; air: water partition 
coefficient; pH dependent 
solubility; solubility in 
gastric/intestinal fluid (fed and 
fasted states) 
Available as a standalone ADMET property predictor or within the GastroPlus 
modelling platform  
ALOGPS 2.1F 
(Virtual 
Computational 
Chemistry 
Laboratory) 
http://www.vcclab.o
rg/lab/alogps/ 
Log P; log D; water solubility; 
pKa P 
In addition to calculating the values the software requests predictions from additional 
sources (e.g. KOWWIN, Molinspiration, Dragon X etc.) and displays all predictions to 
enable comparison 
 BiobyteC (Bio-
Loom) 
http://www.biobyte.
com/  
Log P, log D, pKaP,M Includes database of 60,000 measured log P and log D values (various solvents) and 
14,000 pKa values 
ChemIDPlus 
Advanced 
https://chem.nlm.ni
h.gov/chemidplus/ 
Log P, pKa, solubility, vapour 
pressure, m.ptM,P 
National Institute of Health, US National Library of Medicine database and predicted 
values 
ChemspiderF 
(Royal Society of 
Chemistry) 
http://www.chemspi
der.com/  
[45] 
Log P; water solubility 
pKa, vapour pressure, Henry’s 
law constantM,P 
Comprehensive resource for over 60 million chemical structures; includes 
experimental data where available and links to predictions from EPISUITE, ACD/Labs 
and ChemAxon 
ChemAxonC https://chemaxon.co
m/ 
Log P; log D; 
hydrophilic:lipophilic balance; 
water solubility; hydrogen 
bond donor / acceptor; pKaP 
Chemical property predictors are one component in a suite of chemoinformatics 
tools. 
Corina 
SymphonyF 
(MN-AM) 
https://www.mn-
am.com/ 
[46] 
Log P; hydrogen bond donor / 
acceptor parametersP 
A chemoinformatics application for generating multiple chemical descriptors 
Computational 
Toxicology 
DashboardF 
https://comptox.epa
.gov/dashboard 
[47] 
Log P, m. pt, b. pt, vapour 
pressure, etcM,P 
Provided by United States Environment Protection Agency (USEPA); The dashboard 
hosts a repository of data for 762,000 chemicals and links to other data sources; 
includes physico-chemical properties, activity, fate, hazard and other data. 
EpisuiteF 
(US-EPA)) 
https://www.epa.go
v/tsca-screening-
tools/epi-suitetm-
estimation-program-
interface 
Log P; water solubility, vapour 
pressure, Henry’s law 
constantM,P 
Extensive database of measured values; atom/fragment contribution method to 
estimate log P; water solubility calculated using log P and appropriate correction 
factors 
MOE (Molecular 
Modelling 
Environment)F 
https://www.chemc
omp.com/MOE-
Calculates >400 molecular 
descriptors including physico-
chemical properties, 
Chemical Computing Group, Canada (interfaces to other software such as Gaussian, 
GAMESS, MOPAC and ADF) 
 Molecular_Operatin
g_Environment.htm 
Topological Polar Surface Area 
(TPSA), log P, log D, pKa, 
electronic effects such as 
hydrogen bonding capacity, 
partial charges, dipole 
moment etc. 
MokaC 
Molecular 
Discovery 
http://www.moldisc
overy.com/software/
moka/  
pKaP       Calculates pKa using a method trained on more than 25,000 pKa values (algorithm 
uses descriptors derived from GRID molecular interaction fields) 
MolinspirationF http://www.molinspi
ration.com/ 
Log P; hydrogen bond donors / 
acceptors; TPSA; volume 
Interactive web service to calculate molecular properties, visualise and manipulate 
structures 
OECD QSAR 
toolboxF 
https://www.qsarto
olbox.org/  
Multiple physico-chemical 
propertiesM,P  
The Toolbox has been developed to help fill gaps in (eco) toxicity data. It includes a 
large compilation of donated databases (for both properties and biological activities)  
PubChem Open 
Chemistry 
databaseF 
https://pubchem.nc
bi.nlm.nih.gov/searc
h/ 
Multiple physico-chemical 
properties including log P, 
TPSA, water solubility, pKa, 
vapour pressureM,P 
A comprehensive data resource including chemical and physical properties, uses, 
toxicity, safety information etc. 
Schrodinger:C 
QikProp 
https://www.schrodi
nger.com/  
pKa; Log P; water solubility Schrodinger software encompasses a range of molecular modelling packages for 
drug design includes prediction of physico-chemical and ADME properties 
SwissADMEF http://www.swissad
me.ch/   [48] 
Multiple physico-chemical 
properties including log P 
(various methods of 
calculation), water solubility, 
Webservice from the Swiss Institute of Bioinformatics  
 TPSA; no. hydrogen bond 
donors / acceptorsP 
FFreely available; CCommercial; PPredicted value; MMeasured value 
Additional sources of information: 
 The above is not an exhaustive list - many other resources are available. As part of the ANTARES project (Alternative Non-Testing methods Assessed for 
REACH Substances) extensive lists of software capable of predicting physico-chemical (and other properties) have been compiled; these lists of software 
are available at:  http://www.antares-life.eu/index.php?sec=modellist  
 The Computational Chemistry List (http://www.ccl.net/chemistry/links/software/index.shtml) is an extensive list of software for calculating a multitude of 
physico-chemical and ADME-related properties, quantum chemical and molecular mechanics based descriptors. The website provides a brief summary of 
the software and a link to the parent websites 
 
  
 Table 3. Resources for information on ADME properties (datasets, models and predictive software)  
Resource Available from Properties / information Additional information 
ACD/PerceptaC ACD Labs 
https://www.acdlabs
.com/products/perce
pta/  
Estimates multiple ADME-PK related 
parameters including absoprtion, 
bioavailability, Cp (T), Tmax and Cp (max), 
AUC, Pgp substrate specificity, Vd, protein 
binding. Blood Brain Barrier (BBB) 
penetration etc. 
Multiple modules available for predicting both physico-chemical 
and ADME related properties. 
ADME databaseC; 
Fujitsu 
http://www.fqs.pl/e
n/chemistry/product
s/adme-db  
[49] 
Interactions of substances with Phase I and 
II metabolising enzymes and drug 
transporters; database of kinetic 
parameters – in vitro assay model (Km, Vmax, 
Ki, Ks, efficiency, IC50, EC50, t½ etc.) 
Data available for > 26,000 substances (72,000 entries for CYPs; 
15,400 for other enzymes); 34,000 entries providing data on >400 
transporters  
ADMETlabF http://admet.scbdd.
com/calcpre/index/  
[44] 
Human intestinal absorption; Caco-2 
permeability; P-gp / CYP substrates and 
inhibitors; bioavailability; plasma protein 
binding; BBB partitioning; volume of 
distribution; t½ , clearance 
Developed by the Computational Biology and Drug Design Group, 
Central South university, China 
ADMET PredictorC 
(SimulationsPlus) 
https://www.simulat
ions-
plus.com/software/a
dmetpredictor/ 
[50] 
Permeability (skin, cornea, gastro-intestinal 
tract, BBB); interactions with OATP1B1 and 
P-gP; plasma protein binding; blood: plasma 
ratio, volume of distribution; fraction 
unbound in microsomes etc.) 
Available as a standalone ADMET property predictor or within the 
GastroPlus modelling platform  
admetSARF http://lmmd.ecust.e
du.cn/admetsar2   
Dataset for ADMET properties curated 
from literature; ADMET-Simulator also 
predicts approx. 50 relevant ADMET 
Comprises both literature data (>210,000 data points for >96,000 
compounds) and predictive software based on regression / 
 [51] endpoints.  (Human intestinal absorption, 
bioavailability, volume of distribution, 
plasma protein binding, clearance, Ki IC50 
etc.) 
classification models to predict approximately 50 ADMET 
endpoints.  
ADME SARfari (EMBL-
EBI)F 
https://www.ebi.ac.
uk/chembl/admesarf
ari     [43] 
Identifies ADME targets; finds 
pharmacokinetic data for input chemical or 
similar compounds 
EMBL-EBI provides a range of data sources including data for 
ADME relevant proteins responsible for metabolism / transport in 
humans and other species 
The ADME databasesF http://modem.ucsd.
edu/adme/database
s/databases_extend.
htm    [52] 
Data for log S,  Caco-2 permeability, blood-
brain permeability, P-gp inhibition, oral 
absorption and bioavailability  
ADME relevant databases developed using data collected from 
literature. 
ADMETNetF http://bioinf.xmu.ed
u.cn/ADMETNet/ind
ex.html     [53] 
Depicts pharmacokinetic pathways for 
drugs; provides data such as half-life, free 
fraction in plasma bioavailability, volume of 
distribution etc.  
Data for 1, 541 drugs; provides external links for additional 
searches on compound of interest (e.g. DrugBank, Drugs.com, 
ChemSpider, admetSAR etc.) 
ADME-APF   http://bidd.nus.edu.
sg/group/admeap/a
dmeap.asp   [54] 
A database of proteins associated with 
drug absorption, distribution, metabolism, 
and excretion 
Provides information on ADME associated proteins e.g. functions, 
similarities, substrates, ligands, tissue distributions and other 
properties; 321 proteins and 964 substrates 
BIOVIA Metabolite: Biovia 
(formerly Accelrys)C 
http://accelrys.com/
products/collaborati
ve-
science/databases/ 
Compilation of in vitro and in vivo metabolic 
data from literature, conference 
proceedings and New Drug Applications 
Comprehensive database on biotransformations (predominantly 
for drugs) 
BrendaF http://www.brenda-
enzymes.org/index.p
hp           [55] 
Extensive database of Vmax, Km, Kcat and 
other parameters related to enzyme 
kinetics. 
Enzyme function data from literature, text mining and external 
databases; >3 million data points, from over 135,000 references; 
links to literature reports 
BBBF     
 Computational Toxicology 
DashboardF 
https://comptox.epa
.gov/dashboard 
[47] 
ADME data to be included in this database 
(ongoing) 
Provided by United States Environment Protection Agency 
(USEPA) 
Cytochrome P450 Drug 
Interaction TableF 
http://medicine.iupu
i.edu/clinpharm/ddis
/clinical-table  [56] 
List of drugs acting as substrates, inhibitors 
(partial ranking as to weak, moderate or 
strong) and inducers of CYP enzymes -  
1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 
3A4,5,7 
Developed as a drug-drug interaction table by Indiana University 
DIDB - Metabolism and 
Transport Drug 
Interaction DatabaseC 
https://www.drugint
eractioninfo.org/ 
[57] 
In vitro and in vivo drug interaction data 
from literature and New Drug Applications 
(NDA) 
Manually curated data relating to drug interactions, developed 
by the University of  Washington  
DrugbankF https://www.drugba
nk.ca/      [58] 
Key ADME properties for drugs e.g. % oral 
absorption, volume of distribution, protein 
binding, metabolic information, t ½, 
clearance etc.     
Data entries for >11,000 drugs with >200 data fields per compound 
(note not all fields are complete for each drug). Includes predicted 
ADMET properties such as absorption, p-glycoprotein and 
metabolising enzyme interactions 
e-PK geneC https://www.drugint
eractioninfo.org/ 
[59] 
Information on the impact of genetic 
variation on parent compound 
pharmacokinetics (i.e. changes in AUC, Cl 
or Cmax for different populations) 
Manually curated from pharmacogenetics literature and New Drug 
Applications; developed by the University of  Washington  
EDETOX databaseF 
 
https://apps.ncl.ac.u
k/edetox/    [60] 
A database of  in vitro and in vivo skin 
penetration data for many compounds, 
including information on skin type, area 
and vehicle 
1,657 in vitro and 844 in vivo records (across all species and 
chemicals) compiled from published literature; developed by the 
University of Newcastle 
Evolvus: Microsomal 
Stability DatabaseC 
http://www.evolvus.
com/products/datab
Liver microsome stability assay data (Clint 
and t½) for drugs and drug-like compounds 
Customisable, commercial database; includes assay specific data 
to assist in silico modelling 
 ases/microsomalstab
ility.html  
curated from literature for rat, mouse, 
human and dog)  
Goodman and Gilman’s 
The Pharmacological 
Basis of Therapeutics 13th 
Edition 
McGraw-Hill 
Publishers (2017) 
ISBN-13: 978-
1259584732 
Appendices provide key pharmacokinetic 
data for commonly used drugs e.g. oral 
bioavailability, urinary excretion, % bound 
in plasma, clearance, volume of 
distribution, half-life, Tmax and Cmax 
Standard pharmacology text book providing references to original 
publications for the data 
 
Hazard Evaluation 
Support System and 
Integrated Platform 
(HESS)F  
http://www.nite.go.j
p/en/chem/qsar/hes
s-e.html       [61] 
 
Metabolic maps and ADME data for 
humans and rats  
National Institute of Technology and Evaluation, Japan; database 
incorporated within OECD QSAR Toolbox  
IDAAPMF http://idaapm.helsin
ki.fi/           [62] 
Integrated database for ADMET and 
adverse effect predictive modelling 
Comprises information on approved drugs, ADMET properties, 
adverse affects and target / affinity data 
KinParDBF 
Joint Research Centre 
European Union 
Reference Laboratory for 
Alternatives to Animal 
Testing (EURL ECVAM) 
https://eurl-
ecvam.jrc.ec.europa.
eu/  
Kinetic parameters (e.g. clearance, half-life, 
AUC) for 100 diverse chemicals  
Includes experimental details for the generation of the data 
Laboratory of Molecular 
Modeling and Design 
(LMMD) DatasetsF 
http://lmmd.ecust.e
du.cn/ 
ADME databases curated from the 
literature with information on blood brain 
barrier (BBB) partitioning, human intestinal 
absorption, P450 inhibitors and non-
inhibitors 
BBB partitioning data for 1,593 compounds; HIA data for 578 
compounds; inhibitor and non-inhibitor information for 27,000 
compounds interacting with 5  CYPs isoforms – 1A2, 2C9, 2C19, 
2D6 and 3A4 – extracted from PubChem 
 The Merck Index On-lineF https://www.rsc.org
/merck-index 
Provides links to original publications for 
individual drugs, including detailed reports 
for pharmacokinetics   
The Merck Index Online, from the Royal Society of Chemistry; 
information on physical and biological properties and structure  
METRABASEF http://www-
metrabase.ch.cam.ac
.uk/  
[63] 
Data on interactions between chemicals 
and proteins relating to metabolism and 
transport; 20 transporters and 13 CYP 
enzymes; identifies substrates and non-
substrates / inhibitors and inducers 
Data extracted from literature and on-line resources for 3438 
compounds; >11,000 interaction records from > 1,211 references; 
developed by the university of Cambridge 
 
Microsomal stabilityC  http://www.evolvus.
com/products/datab
ases/microsomalstab
ility.html 
Database for parameters of liver 
microsomal stability assays like CLint and 
T1/2 for various drug and drug like 
compounds. 
entries for liver microsomes from different organisms (rat, mouse, 
human, dog) are curated 
Obach et al., 2008 http://dmd.aspetjou
rnals.org/content/36
/7/1385 
Clinical IV data  Database for 670 drugs 
 
OECD QSAR toolboxF https://www.qsartoo
lbox.org/   
[64] 
Encompasses a collation of databases 
including data on plasma protein binding, 
absorption, rat and human metabolic data – 
skin and liver  
Data can be accessed from the OECD QSAR Tool box ver 4.2; liver 
and skin metabolism simulators also incorporated 
On-line chemical 
modelling environment -
oCHEM F 
https://ochem.eu/ho
me/show.do 
[65] 
Datasets for many ADME properties (e.g. 
absorption, BBB partitioning, Caco2 
permeability, log P, log D, water solubility, 
plasma protein binding, IC50, CYP 
Inhibition, P-gp substrate activity; 
tissue:blood partition coefficients and time 
dependent tissue-drug concentrations  
Provides an expanding database of experimental results with a 
predictive modelling framework. Users can upload their own data 
and models based on the wiki principle. Large datasets for some 
parameters but much more limited for others e.g. tissue-dug 
concentrations.  
 PharmaInformatic: 
PACT-FC / PPB-DBC 
 
http://www.pharmai
nformatic.com/html/
pact-f.html  
PACT-F provides bioavailability data for 
humans (from clinical trials) and preclinical 
animal studies. PPB-DB provides protein 
binding information  
Comprises 8,296 records for bioavailability and >17,000 data 
records for protein binding from 2,400 publications 
PharmapendiumC: 
Elsevier 
https://www.elsevie
r.com/solutions/phar
mapendium-clinical-
data 
ADME information searchable by terms 
such as % absorption, bioavailability, cell / 
protein binding metabolic transformation, 
tissue distribution, volume of distribution, 
clearance, half-life; humans, birds, fish and 
mammals 
Pharmacokinetic data for approved drugs extracted from drug 
approval packages.  
pkCSMF http://biosig.unimel
b.edu.au/pkcsm/ 
[66] 
Caco-2 / skin permeability, HIA, P-gp / CYP 
substrate / inhibitor; clearance, renal OCT2 
substrate; volume of distribution, BBB 
permeability, fraction unbound in plasma 
Uses graph-based signatures to predict a range of ADMET 
properties  
QikPropC https://www.schrodi
nger.com/products  
Predicts ADME relevant properties (e.g. 
blood brain partitioning, protein binding 
Caco-2 and MDCK permeability) 
Part of a suite of molecular modelling packages for drug design 
(see above) 
SwissADMEF http://www.swissad
me.ch/     [67] 
Multiple ADME–related  properties 
including GI absorption, BBB penetration, 
skin penetration, interactions with P-gp and 
CYPs, drug-likeness characteristicsP 
Webservice from the Swiss Institute of Bioinformatics.   
TRANSFORMERF http://bioinformatics
.charite.de/transfom
er/index.php?site=h
ome    [68] 
Information on metabolism and transport 
of compounds in humans 
Data for interactions with Phase I (4007 reactions) and Phase II 
(431 reactions) enzymes and drug transporters (1,158 
interactions) for 2,800 drugs 
TP-SearchF  http://togodb.dbcls.j
p/tpsearch    [69] 
Transporters database  Information on substrates and inhibitors for a wide range of 
transporters 
 US FDA drug database - 
drugs@fdaF (Orange 
Book) 
https://www.accessd
ata.fda.gov/scripts/c
der/ob/index.cfm  
In vitro and in vivo ADME data Clinical PK data also available 
UCSF-FDA TransportalF http://transportal.co
mpbio.ucsf.edu/abo
ut/    [70] 
Information on transporter expression, 
location, substrates, inhibitors and 
interactions 
University of California, San Franciso-Food and Drug 
Administration resource developed as part of FDA-led Critical Path 
Initiative 
VolSurfF http://www.moldisc
overy.com/software/
vsplus/     [71] 
Creates 128 molecular descriptors from 3D 
Molecular Interaction Fields (MIFs) related 
to ADME 
Passive intestinal absorption, BBB, solubility, PPB, Vd, and 
metabolic stability models available. 
VNN ADMETF  https://vnnadmet.bh
sai.org/vnnadmet/lo
gin.xhtml  [72] 
 Predicts ADMET properties and facilitates 
building of new models based on variable 
nearest neighbour (vNN) methodology 
This platform comprises 15 models for ADMET prediction models  
FFreely available; CCommercial  
Additional sources of information: 
 Many of the bespoke ADME / PBK modelling software packages are capable of predicting relevant physico-chemical or pharmacokinetic properties.  
 Madden et al., 2017 [73]: Incorporates a review of data sources and software providing information relating to metabolism in skin and liver e.g. prediction of 
metabolites, CYP isoforms involved in biotransformation, predictive models for kinetic parameters etc. 
 Mostrag-Szlichtyng and Worth, 2010 (http://publications.jrc.ec.europa.eu/repository/handle/JRC58570):  An extensive review of QSAR models and software 
available to predict ADME properties, with an emphasis on methods to estimate oral bioavailability, human intestinal absorption, blood brain barrier 
penetration, plasma protein binding, metabolism and excretion. The review provides references for: 16 ADME related databases;15 datasets for ADME; 13 
software tools for predicting input parameters; 41 software tools for ADME prediction (note that some of these data resources are no longer available); 8 
rules of thumb for intestinal absorption / blood brain barrier partitioning; 37 models for human intestinal absorption; 13 models for bioavailability; 77 models 
for BBB partitioning; 28 models for plasma protein binding; 87 models relating to metabolism and 16 models relating to excretion. 
 Patel et al., 2018 [20]: As part of an investigation into the reproducibility of QSAR models, Patel et al compiled a list of 80 different models for 31 ADME 
related endpoints and assessed these models against the OECD principles for validation of QSARs  
  Przybylak et al., 2018 [22]: Over 140 ADME datasets were collated in this study and were assessed for their suitability for modelling purposes. Many of these 
datasets represent a compilation of previously published datasets that have been curated by various authors. 31 were considered to be “benchmark” datasets 
for 24 different ADME properties; each of these datasets is available in Excel spreadsheet format as Supplementary Information from the article.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 4. Resources for obtaining reference values for physiological/anatomical parameters and model structures for specific organs  
Resource Reference Properties / Information Additional Information 
Abduljali et al., 
2012 
 [26]   Key parameters for PBK modelling in pregnancy 
according to gestational age. 
Integration of data from extensive literature review of changes 
in anatomical, physiological and metabolic parameter changes 
during normal pregnancy. 
Abduljali et al., 
2018  
[24], [25] Key biometric / morphological and compositional 
parameters to develop PBK models for a foetus at 
different gestational ages 
Integration of data from extensive literature review providing 
data on size, height, weight, surface area, abdominal and head 
circumference, body composition. 
Ball et al., 2013  [27]  PBK model structure for blood brain barrier (BBB) 
penetration based on literature review of existing 
PBK models for CNS 
Includes evaluation of the applicability of in-vitro-in vivo 
extrapolation in PBK models for BBB penetration 
Brown et al., 
1997  
 [23]  Physiological and anatomical parameter reference 
values (and ranges for values) for mice, rats, dogs 
and humans. Organ weights, composition, 
regional blood flows, volumes, cardiac output, 
respiratory parameters etc. 
A comprehensive, key reference source for physiological and 
anatomical reference values in multiple species, expanding upon 
previous data collations and providing information on potential 
variability of the parameters.  
Chetty et al., 
2018 
[74] PBPK considerations for geriatric population Potential use of PBPK models to inform dose adjustments in 
elderly 
Darwich et al ., 
2014  
[75] Enterocyte turnover in humans, rabbits, guinea 
pigs, rats, hamsters and mice 
Collation of enterocyte turnover values in different species; 
turnover influences level of metabolising enzymes in gut wall 
which can be particularly relevant in drug-drug interactions 
Gentry et al., 
2005  
 [76] Physiological values for PBK modelling (organ 
weights / volumes, ventilation, food / water 
intake, blood flows, bile flow, creatinine 
clearance, glomerular filtration rate) in neonatal 
and young rats and mice 
Physiological parameters collated from literature reports are 
available in database format upon request to the corresponding 
author. 
 Gaohua et al., 
2015  
[30] Organ model structures, anatomical and 
physiological data for lung 
Model developed to predict pharmacokinetics of anti-
tuberculosis drugs in lung. Model embedded within Simcyp 
simulator. 
Gaohua et al., 
2016 
 [28]  Model structure and parameters for a four-
compartment permeability-limited PBK model for 
brain. 
Model performance investigated using paracetamol and 
phenytoin; Model embedded within Simcyp simulator. 
Hall et al., 2011 [77] Organ volumes, blood volumes and blood flow 
rates for mice, rats, rhesus monkeys, pigs and 
humans  
The paper describes the development of a whole-body 
physiologically-based framework that uses novel physiological 
scaling laws to improve interspecies extrapolation. 
Heikkinen et al., 
2015  
 
 [78] Quantified levels of cytochrome P450 and uridine 
diphosphate glucuronosyltransferase enzymes in 
Beagle dog liver and intestine 
Enables comparison of enzyme levels between humans and dogs 
to assist interspecies scaling of pharmacokinetic properties 
ICRPP http://www.icrp.org/pu
blication.asp?id=ICRP%2
0Publication%2089 
Age and gender- specific anatomical and 
physiological reference values 
A publication of the International Commission on Radiological 
Protection (ICRPP) to provide inputs for dosimetry calculations. 
Interspecies 
databaseF 
https://www.interspeci
esinfo.com/ 
 
Anatomical, physiological and biochemical data 
for mouse, rat, rabbit, dog, monkey and pig 
Developed by National Institute for Public Health and the 
Environment (RIVM) and the Dutch Ministry of Health, Welfare 
and Sports; provides physiological parameters for mouth, 
oesophagus, stomach, small and large intestine, liver, 
gallbladder, kidney and lung compiled from literature 
Johnson et al., 
2005  
[79] Models for liver volume from birth to adulthood  Meta-analysis of published data / models collated from 5,036 
subjects including investigation of covariates (age, gender, 
ethnicity)  
Lu et al., 2016 [32] Corpus of information on PBK models for 307 
chemicals published in literature 
Enables identification of “similar” compounds that may serve as 
templates for PBK models; provides references for existing 
published models 
 PBK 
Knowledgebase 
National Center 
for Health 
StatisticsF  
https://www.cdc.gov/gr
owthcharts/clinical_cha
rts.htm 
Growth charts for 0-2 yrs and over 2yrs (length, 
height, BMI, head circumference) 
Links to World Health Organisation growth charts for 0-2yrs and 
United States Centers for Disease Control and Prevention growth 
charts for older than 2yrs  
Pilari et al., 
2017  
[31] Organ model structures, anatomical and 
physiological data for testes and thyroid 
Model validated using data for fentanyl, alfentanil, 
omadacycline, amiodarone, desethylamiodarone, 
propylthiouracil 
Price et al., 
(2003)  
[80] Volumes and blood flows for a range of organs and 
tissues, cardiac output and inhalation rate  
Database with accompanying software for retrieving 
physiological parameters for PBK modelling accounting for inter-
individual variation 
Polak et al., 
2012 
[81] Dermal absorption model  The effect of penetration enhancers, site of application, gender 
and ethnic variations incorporated  
Thomson et al 
2009 
[82] Age-specific organ volumes, blood flows, 
glomerular filtration rates for healthy and healthy-
impaired elderly subjects. 
Physiological parameter values collated from 155 publications 
available as a Microsoft ACCESS database.  
Tylutki et al., 
2015 
[83] Cardiac distribution of >200 drugs Drug concentrations in cardiac tissue obtained from cardiac 
surgery and forensic study data.  
Tylutki et al., 
2017  
 
[84] 4 compartmental  heart model (epicardium, 
midmyocardium, endocardium, pericardial fluid) 
Models account for CYP 450 metabolism in heart.  
 
 
 US EPA 
Physiological 
Information 
Database (PID)F 
 
https://cfpub.epa.gov/n
cea/risk/recordisplay.cf
m?deid=202847&CFID=
90333472&CFTOKEN=8
3385957  
Physiological parameter values for humans and 
laboratory animals across life stages 
Database (Microsoft ACCESS) created using data collated from 
extensive literature search and quality assured by independent 
contractor. Also available via HERO 
https://hero.epa.gov/hero/index.cfm website 
Zakaria et al.,  
2018  
[29] Model structure and parameter values for a four-
compartment PBK model for brain 
A region specific PBK model for brain developed using 
compartments for frontal cortex, hippocampus, “rest-of-brain” 
and cerebrospinal fluid.  
Additional sources of information: 
 Note that PBK modelling software inherently includes physiological parameters for the generation of models, many of the model structures and 
parameters reported above have been incorporated into commercial software – refer to table 8 for example software and capabilities. 
 Individual PBK models have been generated for hundreds of compounds (many of these have been collated within the publication of Lu et al - see above), 
however there are many other publications for existing PBK models that can also provide key information on models’ structure and parameters that may 
be applied to the development of new models. 
 
 
  
 Table 5. Dedicated PBK modelling software  
Software Available from Brief summary of capabilities 
CloeC Cyprotex (Evotec AG) 
https://www.cyprotex.com/insilico/phy
siological_modelling/cloe-pk/  
Predicts concentration-time profiles in plasma and 14 organs/tissues using in vitro ADME and 
physico-chemical data; models available for human, rat and mouse 
Cosmos KNIME 
workflowF 
http://www.cosmostox.eu/home/welco
me/ 
Physiologically-Based Kinetic (PBK) models to simulate concentration-time profiles and internal 
dose metrics for dermal or oral exposure scenarios 
High 
Throughput 
Toxicokinetics 
(Httk)F 
https://cran.r-
project.org/web/packages/httk/index.h
tml 
Provides data tables and functions for simulation;  facilities to parameterise PBK and one-
compartment TK models for multiple chemicals and species; in vitro-in vivo extrapolation of HTS 
data; models can be exported for use with other simulation software 
GastroPlusC Simulations Plus, Lancaster, CA 
https://www.simulations-
plus.com/software/overview/  
Comprises 10 modules including: PBPKPlus – enables PBPK modelling and IVIVE, can be 
parameterised for different disease states and age groups. ADMET Predictor – predicts physico-
chemical and ADME properties. Additional Dosage Routes – simulates oral cavity, dermal, 
pulmonary ocular and intramuscular administration. PKPlus – estimates PK parameters  
IndusChemFateF 
(CEFIC LRI) 
http://cefic-
lri.org/toolbox/induschemfate/  
(Microsoft Excel spreadsheet files) 
Generic PBK model (first tier or screening level tool); estimates tissue body fluid concentrations 
following oral, dermal or inhalational exposure to volatile or semi-volatile chemicals 
MEGenF http://xnet.hsl.gov.uk/megen Web application to generate PBK model equations; parameters may be retrieved from the 
integrated database or obtained from literature; output available in MATLAB, ACSL  or other 
format 
PBPK Model https://www.trentu.ca/academic/amins
s/envmodel/models/PBPK.html 
[85] 
The Canadian Centre for Environmental Modelling and Chemistry; Excel-based PBPK 
spreadsheet, parameterised for human male 
 Simcyp 
SimulatorC 
 
Certara, Princeton New Jersey 
https://www.certara.com/software/phy
siologically-based-pharmacokinetic-
modeling-and-simulation/simcyp-
simulator/?ap%5B0%5D=PBPK 
PBK modelling and simulation platform; links in vitro data to in vivo ADME to predict PK/PD 
interactions for small molecules and biologics. Incorporates databases of genetic, physiological 
and epidemiological information to enable simulation of different populations (includes modules 
for paediatrics and rat, dog and knock-out mouse). Incorporates an automated sensitivity 
analysis tool that can be used to assess influence of changing specific parameters. Predicts ADME 
parameters such as oral, dermal, pulmonary absorption, clearance. Includes: ADAM (advanced 
dissolution, absorption and metabolism) model – predicts variability in bioavailability using 
physico-chemical properties and in vitro data; dissolution (from various dosage forms) for oral 
absorption; models also available for skin and pulmonary absorption; BBB partitioning, 
metabolism, clearance etc. 
PK-Sim and 
MoBiF 
Open Systems Pharmacology Suite 
(Bayer) 
http://www.systems-
biology.com/products/PK-Sim.html 
 
PK-Sim: PBK modelling tool with integrated database of anatomical and physiological parameters 
for humans, mouse, rat, dog and monkey. Uses interchangeable building blocks to enable 
alternative scenarios to be considered e.g. changing from animal model to human population or 
i.v. dose to controlled release. 
Mobi: Software for multiscale physiological modelling and simulation. A range of biological 
models can be imported (e.g. PBK model imported from PK-Sim) or developed de novo; Software 
is compatible with Matlab and R. 
PLETHEM 
(Population 
Lifecourse 
Exposure-To-
Health-Effects 
Model)F 
ScitoVation 
http://scitovation.com/plethem.html  
Open source R package incorporating: a generic 11 compartment diffusion limited PBPK model; 
a high-throughput IVIVE model to extrapolate in-vitro measured point of departure to equivalent 
exposures; an in-vitro to in-vivo model to extrapolate in-vitro measured metabolism values to 
predicted in-vivo values; population variability modelling; databases of age-dependent 
physiological and metabolic parameters; QSAR models to estimate partition coefficient 
SimuloF  https://exprimo.com/simulo  It is a PK-PD Disease model simulator. It provides ability to perform Monte Carlo simulations and 
evaluations of study designs and dosing strategies.  
FFreely available; CCommercial 
 
 Table 6. Additional software / applications to assist in PBK or PK/PD modelling 
Software Available from Brief summary of capabilities 
A4SF 
(Accelera for 
Sandwich) 
Reported in publication of Germani et al., 2013 
[86] 
Mat-lab based PK/PD simulator (incorporates 10 PK models; generates plasma 
concentration-time profiles, AUC, Cmax, t½ etc.) 
 
ADAPTSF Biomedical Simulations Resource, University of 
Southern California,  [87] 
https://bmsr.usc.edu/software/adapt/  
Individual and population PK/PD modelling application 
BiokmodF http://diarium.usal.es/guillermo/biokmod/  
 
Mathematica-based packages for modelling linear and non-linear biokinetics; differential 
equation solver 
ChemPKTM V.2C Cyprotex, Cheshire, UK 
https://www.cyprotex.com/insilico/physiologic
al_modelling/chempk 
Predicts oral and i.v pharmacokinetic data from structure, using a KNIME workflow; 
calculates 10 tissue partition coefficients, absorption, renal clearance and metabolism; 
predicts clearance, t½  volume of distribution AUC, Cmax, Tmax etc. 
GastroPlusC Simulations Plus, Lancaster, CA 
https://www.simulations-
plus.com/software/overview/  
[88] 
PKPlus module – estimates PK parameters for 1, 2 3-compartment or non-compartmental 
models; fitted parameters include 1st order absorption rate, lag time and bioavailability 
(can be linked back to GastroPlus model) 
INTELLIPHARMC Intellipharm, LLC, Niantic, USA 
https://www.intellipharm.com/physiologically-
based-pharmacokinetic-modeling.htm  
Combines simulation of drug dissolution, precipitation, absorption and gastric motility 
with bioavailability, clearance, and volume of distribution as coupled differential 
equations; provides open source code for PBK models. 
 Maxsim2C http://www.maxsim2.com/      [89] Interactive PK/PD modelling software enabling investigation of consequences of varying 
physico-chemical, physiological or anatomical features; incorporates common PK and PD 
models. 
MetStabOnF 
 
http://skandal.if-
pan.krakow.pl/met_stab_pred/   [90] 
 in silico qualitative evaluation of metabolic stability (T1/2, CL) 
MagnoliaF https://www.magnoliasci.com/ Magnolia provides the tools for developing models using an equation-based modeling 
language, scripting the execution of simulations using either the Python programming 
language. 
NONMEM 
(including 
PREDPP)C 
ICON, Dublin 
https://www.iconplc.com/innovation/nonmem/  
[91] 
NONMEM – generic package for simulating / fitting data; PREDPP provides subroutines 
for predicting PK/PD data. 
Pheonix 
WinNonlin and 
Pheonix NLMEC 
Certara, Princeton, New Jersey 
https://www.certara.com/wp-
content/uploads/Resources/Brochures/BR_Pho
enixWinNonlin.pdf 
WinNonLin - Industry standard integrated tool for non-compartmental analysis, PK/PD 
modelling; NLME – non-linear mixed effect modelling and simulation software 
PKfit for RF https://cran.r-
project.org/src/contrib/Archive/PKfit/  
Pharmacokinetic tool for data analysis in R 
PKPD Tools for 
ExcelF 
Add on for Microsoft Excel 
http://pkpdtools.com/excel/downloads/ 
Add-on to assist PK/PD simulation and modelling within Microsoft ExcelC.  
PopGenF Bayer 
http://xnet.hsl.gov.uk/popgen/     [92] 
Virtual human population generator to predict realistic variation in anatomical and 
physiological parameters across populations. 
PDx-PopC  https://www.iconplc.com/  Requires NONMEM to run  
 RVISF http://cefic-lri.org/projects/aimt7-rvis-open-
access-pbpk-modelling-platform/ 
 
Open source syntax R or C++ for the analysis of structure and performance of PBPK models 
SAAM-II 
(Simulation 
Analysis and 
Modelling) 
Version 2.3C 
TEG, The Epsilon Group, Virginia 
https://tegvirginia.com/software/saam-ii/  
 [93] 
Development and statistical calibration of compartmental models; population kinetics; 
automatic generation of equations from model structure 
 
 
FFreely available; CCommercial 
Additional sources of information: 
 The website for Pharmacokinetic and Pharmacodynamic Resources (Boomer.org) https://www.pharmpk.com/soft.html provides a summary of more than 
100 software applications relevant to pharmacokinetic modelling. The software listed includes a range of applications from bespoke PBK modelling 
packages, such as SimCYP, to general differential equation solvers frequently used in PBK modelling, such as Berkeley Madonna. The resources given in 
table 6 include (amongst others) some of the packages identified by Boomer.org. 
 
 
 
 
 
 
 
 
 Table 7. Examples of mathematical modelling software used for PBK model building or PK/PD analysis 
Resource Available from  Brief summary of capabilities 
Berkley 
MadonnaC 
Berkeley, CA  
https://berkeley-madonna.myshopify.com/  
[94] 
Generic differential equation solver capable of constructing complex models; 
automatic graphing of results; parameter estimation from curve fitting; sliders can 
investigate influence of changing different parameters 
Cossan-X https://cossan.co.uk/ Generic package for quantifying uncertainty; sensitivity and reliability analysis  
GNU MCSIMF GNU project  
https://www.gnu.org/software/mcsim/mcsim.html  
Generic modelling and simulation program; solves user specified linear and 
nonlinear equations 
MatlabC 
(SimBiology)C  
MathWorks, Inc., Natick, MA 
https://www.mathworks.com/products/matlab.html  
[95] 
Modelling and simulation tools focussed on PK/PD and systems biology; library of 
common, customisable PK models; simulates time course of chemicals; model 
parameters estimated by fitting to experimental data; individual or population 
models; can perform sensitivity analysis 
Perl-speaks-
NONMEM (PsN)F 
https://uupharmacometrics.github.io/PsN/  
[96] 
A collection of Perl modules and programs for developing non-linear mixed effect 
models using NONMEM 
RF 
(RStudio)F 
The R Project from the R foundation 
https://www.r-project.org/about.html  
RStudio – integrated development environment for R 
https://www.rstudio.com/products/rpackages/  
Freely available software with a network of users continually adding new 
applications for use by the community; statistical analysis (linear and nonlinear); 
graphing techniques; for examples httk and PKfit for R 
SigmaPlot 
TransformsF 
http://www.sigmaplot.co.uk/products/sigmaplot/ 
transforms.php 
Resource for manipulating data within a worksheet; plotting, transforming and 
fitting data 
 
 FFreely available; CCommercial 
 
Table 8. Example methods for identifying similar chemicals  
Resource Available from Brief summary of capability 
Ambit 2F http://cefic-lri.org/toolbox/ambit/  Includes database of >450,000 chemical structures, identifies similar chemicals based on 
Tanimoto similarity; identifies common substructures 
ChemAxonC  https://chemaxon.com/products/ [97] Extended-connectivity fingerprints; maximum common substructure searching 
CheS-MapperF http://ches-mapper.org/      [98] Enables clustering of molecules based on similar properties; a range of descriptors can be 
calculated (Java application) 
ChemMine 
ToolsF 
http://chemmine.ucr.edu/    [99] Performs clustering based on structural / physico-chemical similarity or user defined 
criteria; search against PubChem Compound Database using fingerprints 
Ellison (2018)  [34] A method to select source chemicals with existing PBK-related information that are similar 
to target chemicals where data are lacking using structural and functional similarity 
Leadscope 
Toxicity DbC 
https://www.leadscope.com/toxicity_da
tabase/              [100] 
Database contains over 180,000 chemicals; capability for similarity and common 
substructure searching  
Lester et al., 
(2018) 
  [35] Rating rules for selecting source chemicals with existing PBK-related information that are 
similar to target chemicals where data are lacking 
Lu et al., PBK 
KnowledgebaseF 
 [32] Incorporates facility to identify similar chemicals from the Knowledgebase based on 
physico-chemical properties 
MOE (Molecular 
Modelling 
Environment)C 
https://www.chemcomp.com/MOE-
Molecular_Operating_Environment.htm 
[101] 
Performs similarity searches using various fingerprint methods in 2D and 3D; MACCS and 
shape fingerprints 
 OECD QSAR 
ToolboxF 
https://www.qsartoolbox.org/  [102] Assists grouping of chemicals based on similarity (using physico-chemical, structural or 
mechanistic properties) 
PubChem Open 
Chemistry 
databaseF 
https://pubchem.ncbi.nlm.nih.gov/searc
h/search.cgi   [103] 
2D and 3D similarity searching; clustering of similar molecules using dendrogams 
RDKit / KNIMEF http://www.rdkit.org/docs/Overview.ht
ml    [104] 
Incorporates multiple methods to identify similar chemicals using both 2D and 3D methods 
(Daylight-like atom pairs, topological torsions, Morgan algorithm, “MACCS keys”, extended 
reduced graphs, shape-based similarity, etc.) 
Therapeutic 
Target DB (TTD)F 
https://db.idrblab.org/ttd/ttd-
search/drug-similarity         [105] 
Structural similarity search for drugs using Tanimoto index 
ToxmatchF https://sourceforge.net/p/toxmatch/cod
e/ci/master/tree/                [106] 
Open-source software encoding a range of structural and descriptor-based similarity 
indices enabling grouping of chemicals. Results can be viewed as scatter plots, pair wise or 
composite similarity histograms; similarity matrices can be exported 
ToxRead 
(VEGA)F 
http://www.toxread.eu/    [107] Identifies most similar compounds from database using similarity metric developed within 
VEGA 
FFreely available; CCommercial 
Additional sources of information: 
 Many databases of chemicals (e.g. Chemspider) and packages for retrieving / predicting ADMET information (as identified above) also provide 
the facility to search for similar molecules e.g. admetSAR [108], ADME SARfari, ChemSpider[45], ChEMBL (EMBL-EBI)[109], oCHEM etc. 
 
  
 Figure 1. Conceptual framework of a physiologically-based kinetic model showing necessary inputs of chemical-specific and system-specific properties and a 
typical output concentration-time curve for an individual organ  
 
 
 
